UK regulator eases restriction to Wockhardt’s Nani Daman manufacturing facility

07 Nov 2013 Evaluate

Wockhardt has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom (UKMHRA), whereby the agency has allowed the company to manufacture and supply most of the products manufactured at Survey No 406/4-5-7, Kadaiya, Nani Daman facility and assessed to be critical to public health.

The company had earlier on October 22, 2013 received communication from UKMHRA, whereby the agency had decided to withdraw the previously issued GMP Certificate to the said manufacturing facility.

As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility.

Wockhardt Share Price

1230.95 58.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.